ALDX Relative Valuation
ALDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALDX is overvalued; if below, it's undervalued.
Historical Valuation
Aldeyra Therapeutics Inc (ALDX) is now in the Fair zone, suggesting that its current forward PS ratio of 7.07 is considered Fairly compared with the five-year average of -8.03. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 1.86 to 5.05 according to relative valuation methord.
Relative Value
Fair Zone
1.86-5.05
Current Price：2.78
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.52
P/B
Median3y
2.70
Median5y
2.95
-28.69
FCF Yield
Median3y
-15.36
Median5y
-14.54
Competitors Valuation Multiple
The average P/S ratio for ALDX's competitors is 14.18, providing a benchmark for relative valuation. Aldeyra Therapeutics Inc Corp (ALDX) exhibits a P/S ratio of 7.07, which is -50.15% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Aldeyra Therapeutics Inc (ALDX) currently overvalued or undervalued?
What is Aldeyra Therapeutics Inc (ALDX) fair value?
How does ALDX's valuation metrics compare to the industry average?
What is the current P/B ratio for Aldeyra Therapeutics Inc (ALDX) as of Jun 16 2025?
What is the current FCF Yield for Aldeyra Therapeutics Inc (ALDX) as of Jun 16 2025?
What is the current Forward P/E ratio for Aldeyra Therapeutics Inc (ALDX) as of Jun 16 2025?